Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by juniper88on Jul 16, 2022 12:43pm
148 Views
Post# 34829088

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The list

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The listA biopsy is done on every patient. They did a biopsy on my wife. It is for research purposes but not for screening inclusion. They try their best to pick a tumor that is easiest to get to. If nothing is easily accessible then archival tissue is accepted.
jfm1330 wrote: Turn it the way you want, not directly testing patients for sortilin expression is clearly a subpar way to do this trial. Again, overexpression is relative, with the exact data about overexpression they would better understand what is going on and the relation with efficacy and they would not treat patient for nothing.

I understand this is early and that biopsy in most cases is painful for patients ans can involve some risks of internal hemorrhage. I know it, I got one from the liver and you need to lay down on a bed, not moving, for three hours to be sure it will not bleed inside your body. So I understand all they want is to treat patient with good odds of overexpressing sortilin, but they will have to do things differently in phase II and beyond.


<< Previous
Bullboard Posts
Next >>